The common g-chain (gc) plays a central role in signaling by IL-2 and other gc-dependent cytokines.
INTRODUCTION
Cytokines of the common g-chain (gc) family are critical for development of T lineage cells and depend on gc for cellular signaling (Rochman et al., 2009) . gc deficiency results in a paucity of both mature B and T cells because of impaired signaling by the gc cytokine IL-7 . In fact, IL-7 signaling is necessary for developing lymphocytes to proceed through the pre-pro-B cell stage of B cell differentiation and the CD4 À CD8 À double-negative (DN) stage of thymopoiesis (DiSanto et al., 1995; Peschon et al., 1994; von Freeden-Jeffry et al., 1997) . Impaired IL-7 signaling also profoundly impairs mature T cell survival and homeostasis (Schluns et al., 2000; Tan et al., 2001 ). Because gc is also required for IL-2 and IL-15 signaling, gc deficiency impairs development of FoxP3 + regulatory T cells and NK cells (Heaney and Golde, 1996; Ma et al., 2006; Vosshenrich et al., 2005) and also alters CD4 T helper cell lineage fate and CD8 memory cell differentiation (Rochman et al., 2009 ). Thus, gc governs the generation, differentiation, and homeostasis of all lymphocyte subsets in the adaptive immune system. Although gc expression is necessary for gc cytokine signaling, gc alone cannot bind cytokines and cannot trigger downstream signaling (Minami et al., 1993) . Rather, gc cytokines induce gc membrane proteins to complex with proprietary cytokine receptor subunits, such as the IL-7-specific IL-7 receptor a chain (IL-7Ra) and the IL-2-specific IL-2 receptor b-chain (IL-2Rb), to transduce cytokine receptor signals. Importantly, the magnitude and kinetics of gc cytokine responses are thought to be controlled by the proprietary cytokine-specific receptor subunits and not by gc (Rochman et al., 2009) . For example, IL-7 stimulation affects IL-7Ra expression but does not affect gc expression (Park et al., 2004) , and IL-2 stimulation affects IL-2Ra and IL-2Rb without affecting gc expression (Depper et al., 1985; Siegel et al., 1987) . Consequently, modulation of gc expression is thought to be irrelevant to either the kinetics or magnitude of cytokine signaling. Instead, gc expression levels are thought to be developmentally set and to remain constant during T cell activation and differentiation (Rochman et al., 2009) .
In contrast to this prevailing view, we now report that modulation of gc expression actively contributes to the regulation of cytokine responses. Interestingly, gc exerts its regulatory effects not as a conventional membrane receptor protein but as a secreted protein induced by T cell stimulation. Specifically, we found that activated T cells expressed a gc mRNA splice isoform that resulted in production and secretion of soluble gc ectodomain proteins. Soluble gc inhibited cell signaling by gc cytokines and exacerbated inflammatory responses by promoting differentiation of pathogenic CD4 + Th17 cells both in vitro and in vivo.
Conversely, the severity of Th17-cell-mediated inflammatory autoimmune disease was markedly diminished in mice lacking sgc. Thus, this study identifies a role for gc as an active immunoregulatory molecule whose alternatively spliced form is secreted to dampen signaling by gc cytokines and promote inflammatory T cell immune responses in vivo.
RESULTS
Identification of a gc mRNA Splice Isoform that Produces a Secreted Form of gc T cell activation induces expression of soluble factors such as IL-2 that control immune responses both in trans and in cis (Malek, 2008) . To further understand the role of such soluble factors, we analyzed culture supernatants of TCR-and CD28-stimulated T cells. We found that culture supernatants from activated T cells not only contained IL-2 and TNF-a, but surprisingly also contained large amounts of a secreted form of membrane gc proteins ( Figure 1A ). Although shedding is a classical mechanism of producing soluble forms of membrane proteins (Heaney and Golde, 1996) , this was not the explanation for gc protein secretion, as shown by the fact that inhibition of membrane metalloproteases by TAPI2 treatment to prevent membrane protein shedding failed to prevent expression of soluble gc ( Figure 1A ). Instead, we found that activated T cells upregulated expression of a novel gc mRNA species that encoded a soluble form of gc (sgc; soluble gc) rather than the conventional membrane form of gc (Figures S1A-S1C available online). The gene encoding gc (Il2rg) is composed of eight exons, and the entire transmembrane (TM) domain is encoded in exon 6 . The new gc isoform was generated by alternative RNA splicing that excluded exon 6 to encode a gc protein product with the full-length gc extracellular domain (ED) but without the TM and intracellular domain (ID) (Figures S1A and S1B). Mechanistically, an open reading frame shift at the splice junction of exon 5 to exon 7 created a new 9 amino acid epitope followed by a stop codon. Notably, sgc transcripts were present at low levels in resting T and B cells and were highly expressed in immature thymocytes and NK cells as well as in activated T cells ( Figure S1D ). Interestingly, we also identified alternatively spliced sgc transcripts in human T cells, indicating an evolutionarily conserved mechanism of soluble gc expression and regulation ( Figure S1E ).
To examine whether sgc is expressed in vivo, we tested serum for sgc proteins. C57BL/6 wild-type (WT) and gc-deficient (Il2rg À/À ) sera were immunoprecipitated with total gc-specific antibodies and then probed with gc extracellular domain-specific antibodies (a-gc-ED). As shown in Figure 1B , sgc proteins were detected in WT but not in Il2rg À/À serum. To determine whether serum sgc is a product of alternative splicing, we generated antibodies specific for the 9 residue C-terminal neoepitope, CLQFPPSRI ( Figure 1C ), and used these antibodies to probe anti-gc serum immunoprecipitates. Of note, the 9 residue neoepitope is not present in the mouse proteome (NCBI Blastp analysis, data not shown), and it is unique to the alternatively spliced sgc product. Immunoblot analysis showed immunoreactivity of CLQFPPSRI-specific antibodies with WT but not Il2rg À/À serum ( Figure 1C ). To further examine whether shedding contributes to sgc expression in vivo, we generated mice that were unable to gcTg mice (referred to as mgcTg mice). In mgcTg mice, all gc proteins are expressed from a prespliced, transgenic gc cDNA that encodes only the full-length membrane gc and cannot undergo splicing to produce the splice isoform. mgcTg T cells expressed large amounts of membrane gc mRNA and full-length gc protein, but no alternatively spliced sgc transcripts ( Figures 1D) . Strikingly, serum from such mgcTg mice lacked circulating sgc proteins, revealing that virtually all serum sgc is generated by alternative splicing, with little or no contribution from shedding ( Figure 1E ). Thus, mgcTg mice are sgc deficient, and serum sgc is the product of a posttranscriptional gc splice isoform.
Serum sgc Expression Is Upregulated upon Immune Activation In Vivo
Having identified sgc produced by activated T cells in vitro, we wished to know whether T cell activation would increase sgc expression in vivo. To this end, we assessed serum sgc amounts in BALB/c mice injected with CD3 antibodies (a-CD3) to induce acute polyclonal T cell stimulation in vivo. In fact, serum sgc titers were increased overnight after CD3 antibody injection concomitant with T cell activation even as total T cell numbers were not increased (Figures 2A, S2A , and S2B).
Next, we wished to analyze serum sgc titer in mice with chronically activated T cells. Ctla4 À/À mice contain chronically activated T cells that mediate a lethal lymphoproliferative autoimmune disease (Waterhouse et al., 1995) . We found the amount of serum sgc to be larger in Ctla4 À/À mice than in WT mice (Figure 2B) . Importantly, elevated sgc titer was dependent on the presence of activated T cells and not on Ctla4 deficiency itself, because sgc expression was not elevated in nonautoimmune Ctla4 À/À Cd28 À/À mice that lack activated T cells and consequently are disease free ( Figure 2B ; Tai et al., 2007) . To further assess sgc expression during in vivo immune activation, we also analyzed autoimmune Il2 À/À and CD25-deficient (Il2ra À/À ) mice. Both mouse strains have defective CD4 + regulatory T cell generation that results in massive in vivo T cell activation and lethal autoimmunity (Sadlack et al., 1993; Willerford et al., 1995) . We found that both Il2 À/À and Il2ra À/À mice expressed increased amounts of serum sgc, confirming that sgc expression was elevated during in vivo immune activation ( Figure 2C ).
Collectively, our results demonstrate that serum sgc protein levels are increased during T cell activation in vivo.
Generation of sgc Transgenic Mice
To understand the effect of increased sgc expression, we generated transgenic mice overexpressing sgc in T cells (sgcTg). In sgcTg mice, serum sgc levels were substantially increased ( Figures 2D and 2E ), but T cell numbers and phenotypes were unchanged from WT mice ( Figures 2F, S2C , and S2D). To assess whether in vivo sgc upregulation had any effect on T cells, we stimulated sgcTg CD4 + T cells with PMA/ionomycin and examined their ex vivo cytokine expression profiles. gc cytokines play an instructive role in CD4 effector T cell differentiation (Zhu et al., 2010) , and we wished to know how in vivo exposure to increased sgc would affect T cell function. Interestingly, sgcTg CD4 + T cells contained higher proportions of IFN-g producers than did WT CD4 + T cells ( Figure 2G ). Expression of the Th2 cytokine IL-4, however, was not affected ( Figure S2E ). Notably, sgcTg CD4 + T cells contained a significantly larger population of IL-17-producing cells (p < 0.001), suggesting that increased sgc level promoted a Th1-and Th17-cell-prone proinflammatory environment ( Figure 2G ), but this could also reflect an increased presence of memory cells. Importantly, such settings were not created by defects in FoxP3 + CD4 + Treg cells as shown by the fact that both development and function of Treg cells were unaffected in sgcTg mice (Figures S2F and S2G) .
sgc Is Proinflammatory and Exacerbates EAE Pathology Because IL-17-producing Th17 cells are potent inducers of cell-mediated autoimmunity (Harrington et al., 2005; Park et al., 2005) , we wished to know whether sgc would promote autoimmunity. Experimental autoimmune encephalomyelitis (EAE) is a cell-mediated neuroimmunological disease that is largely mediated by Th17 cells and serves as an experimental model for human multiple sclerosis (Goverman, 2009 ). Injection of MOG peptides results in the activation and brain infiltration of autoreactive lymphocytes, which, in our hands, induced paralysis that peaked around day 5 after onset of the disease. Strikingly, when assessing serum sgc expression in EAE-induced mice, we found increased sgc levels in diseased mice ( Figure 3A ). To understand whether increased sgc expression contributed to or was the consequence of EAE pathology, we assessed disease progression and found sgcTg mice to be significantly more susceptible to EAE than control mice (p < 0.001) ( Figure 3B ). In fact, in every parameter examined, sgcTg mice displayed a more pronounced phenotype than did WT mice. Specifically, we found in sgcTg mice that EAE severity worsened, disease progression accelerated, and disease recovery was substantially delayed ( Figure 3C ). Moreover, we found increased numbers of spinalcord-infiltrating CD4 + T cells, which correlated with dramatically increased percentages and numbers of Th1 and Th17 cells and IL-17, IFN-g double-producing CD4 + T cells (Figures 3D and 3E) . Taken together, these results indicate that sgc enhances inflammatory immune responses and increases differentiation of pathogenic Th17 CD4 + effector cells in vivo.
sgc Impairs IL-2 Signaling Having observed that sgc expression exacerbated T-cell-mediated autoimmune diseases in vivo, we wished to determine the effect of soluble gc proteins on the generation of inflammatory Th17 cells. Th17 cell differentiation is negatively regulated by IL-2 signaling (Laurence et al., 2007) and is increased by inhibition of IL-2 signaling (Chen et al., 2011; Pandiyan et al., 2007) . Therefore, we wished to know whether increased Th17 cell generation in sgcTg mice was the result of diminished IL-2 signaling.
To this end, we produced sgc as recombinant proteins (rsgc) ( Figure S3 ). Importantly, we found that rsgc proteins were expressed as disulfide-linked homodimers ( Figure 4A ), and that the same was true for endogenously produced sgc proteins in serum ( Figure S4A ). In fact, alternative splicing of gc in both humans and mice creates a C-terminal cysteine residue that promotes dimerization of sgc proteins (Figures S1A and S1E). Therefore, unlike membrane gc proteins, sgc proteins exist as dimers.
Because gc has no affinity for IL-2 (Minami et al., 1993) , soluble gc would not diminish IL-2 signaling by binding free IL-2. Thus, we wished to know whether sgc might diminish IL-2 signaling by binding to IL-2 receptor proteins on the cell surface. To test this idea, we performed surface plasmon resonance (SPR) studies with purified rsgc on immobilized IL-2Rb extracellular domain (ED) proteins. Strikingly, SPR analysis showed that sgc proteins directly bound to IL-2Rb-ED and that dimeric sgc proteins bound much more strongly (K d of 16.6 ± 5.5 mM) than monomeric sgc (K d of 695 ± 76 mM) ( Figure 4B ). Of note, we consider that the theoretical affinity of sgc binding measured by in vitro SPR study reflects only the minimum potential affinity of sgc for IL-2Rb and that sgc would bind to actual cell surface IL-2Rb with much higher affinity under physiological conditions. 
Immunity Soluble gc Receptor Controls Cytokine Signaling
To further assess whether sgc directly binds to T cells, we utilized flow cytometry. To do so, we examined TCRb + mature thymocytes of mice with conditional deletion of gc in DP thymocytes (Il2rg fl/fl E8 III Cre) because they lack surface gc expression ( Figure S4B ; McCaughtry et al., 2012) . Notably, incubation of Il2rg fl/fl E8 III Cre thymocytes with rsgc proteins revealed direct binding of sgc to the surface, which we visualized by staining with gc-specific antibodies ( Figure 4C ) and which was still detectable at 0.06 mg ($10 nM) ( Figure 4D ). More importantly, addition of IL-2 significantly increased (p < 0.0001) sgc binding to Il2rg fl/fl E8 III Cre cells ( Figures 4C and 4D ), indicating that sgc affinity to IL-2Rb is increased by IL-2. In sum, sgc proteins, especially dimeric sgc proteins, directly bind to surface IL-2Rb chains, especially in the presence of IL-2.
To directly test whether sgc binding to IL-2Rb suppressed IL-2 signaling in T cells, we assessed IL-2-induced STAT5 and AKT phosphorylation in the presence or absence of rsgc (Malek, 2008) . We found that rsgc effectively suppressed downstream IL-2 signaling ( Figure 4E ) and that rsgc-induced impairment of IL-2 signaling reduced IL-2's biological effects on T cells. In mice, naive CD8 + T cells respond to IL-2 by vigorous proliferation (Cho et al., 2010) . We confirmed such IL-2-induced proliferation in purified CD8 + T cells and found that rsgc suppressed IL-2-driven proliferation in the same cells ( Figure 4F ), demonstrating a direct inhibitory role of sgc in IL-2 signaling. Thus, by binding to IL-2Rb proteins on the cell surface, sgc prevents association with membrane gc proteins to impair IL-2 signaling ( Figure S4C ). 
Immunity
Soluble gc Receptor Controls Cytokine Signaling sgc Promotes Th17 Cell Differentiation by Suppressing IL-2 Signaling To assess the IL-2 inhibitory effect of sgc on Th17 cell differentiation, we analyzed Th17 cell generation by using in vitro cultures in the presence of rsgc. As previously described (Laurence et al., 2007) , recombinant IL-2 potently suppressed, whereas antagonizing IL-2 antibodies substantially enhanced, Th17 cell differentiation ( Figures 5A and 5B) . Importantly, sgc treatment or sgc overexpression had the same effect as IL-2 antibodies as it increased both the proportion of IL-17-producing cells and overall IL-17 expression ( Figures 5B and 5C ). In fact, coincubation of rsgc and antagonizing IL-2 antibodies did not have additive effects, indicating that the Th17-cell-promoting mechanisms of rsgc and IL-2 antibodies were redundant ( Figure 5D ). To further demonstrate that the sgc effect on Th17 cells was due to its inhibition of IL-2 signaling, we analyzed sgc effects on CD4 + T cells from Il2 À/À mice. We stimulated naive Il2 Figure 5E ). Altogether, these results document that sgc promotes Th17 cell differentiation by specifically impairing IL-2 signaling.
sgc Deficiency Ameliorates Th17-Cell-Mediated Inflammatory Autoimmune Diseases Because sgc exacerbated IL-17 expression and inflammation, we wished to know whether the absence of sgc would dampen inflammatory responses that otherwise occurred in WT mice. To this end, we assessed EAE induction in mgcTg mice that express only transgenic membrane gc receptors and lack endogenous sgc proteins ( Figure 1E ). Strikingly, EAE disease progression in mgcTg mice was dramatically reduced compared to WT mice, with delayed disease onset and lower clinical scores ( Figure 6A ). Analysis of spinal-cord-and brain-infiltrating T cells further revealed a significant reduction in inflammatory CD4 + T cell numbers and greatly diminished percentages of IL-17-IFN-g double producers, demonstrating a protective effect of sgc deficiency in mgcTg mice ( Figures 6B and 6C) . Importantly, the severity of inflammatory reactions was markedly reduced in mgcTg mice despite the presence of normal numbers and appearances of peripheral T cells ( Figures S5A and S5B ). To further assess the ameliorative effect of sgc deficiency, we utilized the CD4 + CD45RB hi T cell transfer model of inflammatory bowel disease (IBD) (Powrie et al., 1993) 
. Adoptive transfer of naive T cells into immunodeficient Rag2
À/À mice results in severe autoimmune inflammatory colitis that can be monitored by body weight loss and increased IBD clinical scores (Table S1) . Notably, we found that Rag2 À/À host mice injected with mgcTg
CD4 + T cells had markedly diminished IBD, whereas Rag2
À/À mice injected with WT CD4 + T cells suffered from significant body weight loss, destruction of colon tissues, and rapid deterioration of health ( Figures 6D, 6E , S5C, and S5D). Importantly, adoptively transferred mgcTg CD4 + T cells were still activated in vivo and produced large amounts of IFN-g, but it was specifically the expression of proinflammatory IL-17 that was dramatically diminished in these cells ( Figure 6F ). Thus, sgc-deficient T cells were unable to induce severe autoimmune IBD because of reduced Th17 cell generation. Conversely, T cell expression or overexpression of sgc increased the severity of inflammatory disease ( Figure S5D ). These results reveal that sgc exacerbates in vivo inflammatory immune responses and contributes to the severity of in vivo autoimmune pathology.
sgc Overexpression Impairs T Cell Development and Naive T Cell Homeostasis Although sgc directly binds to LN T cells ( Figure 7A ), resting T cells do not express high levels of IL-2Rb. These data suggested that sgc also bound to receptors for cytokines other than IL-2. Specifically, we considered that sgc might bind to IL-7 receptors because they are highly expressed on all resting T cells. SPR analysis showed that this was indeed the case. We found that sgc proteins directly interacted with mouse IL-7Ra-ED proteins and that dimeric sgc showed a dramatic increase of IL-7Ra-ED binding activity (K d = 3.9 mM) over monomeric sgc proteins (K d = 50.8 mM) ( Figure 7B and Table S2 ).
To further demonstrate sgc binding to surface IL-7Ra proteins, we incubated Il2rg fl/fl E8 III Cre thymocytes with rsgc proteins and assessed rsgc binding to thymocyte subpopulations. TCRb hi mature thymocytes express high levels of IL-7Ra and strongly bound sgc, whereas DP thymocytes do not express surface IL-7Ra and did not bind sgc ( Figure 7C ). To directly show that recombinant sgc specifically bound to IL-7Ra proteins, we examined gc-deficient TCRb hi thymocytes that were additionally deficient in IL-7Ra (McCaughtry et al., 2012) . Indeed, IL-7Ra deficiency substantially reduced sgc binding to sgc-deficient TCRb hi thymocytes ( Figure 7D ), documenting that sgc directly binds and interacts with surface IL-7Ra proteins.
IL-7 is critical for thymopoiesis and impaired IL-7 signaling results in reduced thymus cellularity (von Freeden-Jeffry et al., 1995) . Notably, increased sgc expression in sgcTg mice resulted in decreased total thymocyte numbers ( Figure 7E ). CD25 is highly expressed on immature DN thymocytes but dilutes out with proliferation so that CD25 is normally absent on DP thymocytes. However, sgcTg DP thymocytes still expressed significant amounts of surface CD25, which indicated impaired IL-7 signaling and impaired expansion of DN cells ( Figure S6A ; Crompton et al., 1994) . These results demonstrate that sgc blocks in vivo IL-7 signaling. In further support of an sgc effect on IL-7 signaling, we observed increased T cell apoptosis and reduced percentages and numbers of naive T cells in sgcTg mice ( Figures 7F and 7G ), even as their T cells expressed identical levels of IL-7Ra and other gc family receptors to WT mice ( Figure S6B ). Moreover, adoptive transfer of WT T cells into congenic sgcTg or WT host mice revealed that survival of CD44 lo naive donor T cells was substantially reduced in sgcTg hosts compared to WT hosts ( Figure S6C ). Finally, to directly demonstrate that sgc blocks IL-7-induced survival, we stimulated naive T cells with IL-7 in vitro and assessed the effect of recombinant sgc on cell survival. As shown in Figure S6D , rsgc effectively blocked IL-7-induced T cell survival in vitro. Thus, sgc inhibited IL-7 signaling during both T cell development and peripheral T cell homeostasis.
DISCUSSION
Here we report a regulatory mechanism of gc signaling that tunes T cell responsiveness to IL-2 and IL-7 and potentially to other gc cytokines as well. This regulatory pathway was based on posttranscriptional generation and secretion of the gc extracellular domain that directly bound to gc cytokine proprietary receptors such as IL-2Rb and IL-7Ra, especially in the presence of cytokines, and interfered with cytokine signaling. Importantly, secreted gc proteins required disulfide-linked homo-dimerization for high-affinity binding and inhibition of cytokine signaling. During steady-state conditions, sgc interfered primarily with IL-7-dependent processes, resulting in impaired thymopoiesis and naive T cell survival. During T cell activation, sgc inhibited IL-2 signaling and promoted the development of proinflammatory Th17 cell responses as demonstrated by increased Th17 cell differentiation in vitro and by exacerbation of EAE disease in sgc transgenic mice in vivo. Conversely, in vivo sgc deficiency suppressed Th17 cell differentiation and dramatically reduced the severity of inflammatory autoimmune disease, resulting in markedly improved disease outcomes. Thus, this study identifies sgc 
Immunity
Soluble gc Receptor Controls Cytokine Signaling proteins as endogenous immunomodulators that exacerbate in vivo inflammatory diseases by directly binding to cytokine receptors and dampening T cell responses to gc cytokines. Cytokine signaling in T cells is tightly controlled at many levels. Expression of cytosolic inhibitory molecules, such as SOCS, limits the magnitude and duration of cytokine signaling (Yoshimura et al., 2007) . Upregulation of surface cytokine receptor expression, on the other hand, positively affects cytokine signaling. Secretion of gc proteins now adds another layer of regulatory complexity because sgc expression is upregulated upon T cell activation but, unlike the upregulation of other IL-2 receptor chains that enhance IL-2 signaling, upregulation of sgc suppresses IL-2 signaling. Moreover, soluble gc is unique in its regulatory mechanism because it suppressed IL-2 signaling without binding to the IL-2 molecule itself. This is in contrast to other chains of the IL-2 receptor complex that regulate IL-2 responsiveness by direct interaction with IL-2 (Minami et al., 1993) . Because IL-2 signaling requires membrane gc association with IL-2Rb, sgc binding to IL-2Rb proteins probably blocks IL-2 signaling by preventing recruitment of membrane gc proteins and assembly of signaling-competent IL-2 receptor/membrane gc complexes.
The secreted gc protein is structurally identical to the membrane gc receptor, except for absent transmembrane and intracellular domains. Because ligand binding is mediated by the extracellular domain, it was initially unclear how soluble gc could compete with membrane gc for binding to proprietary receptor proteins. The mechanism was partly revealed by SPR analysis, which showed that dimeric sgc proteins possessed >40-fold increased affinity of binding to IL-2Rb proteins compared to monomeric sgc proteins, which was further enhanced in the presence of cytokines. Thus, serum sgc proteins, which are mostly dimers, are vastly superior in binding to IL-2Rb than membrane gc proteins, which are monomers and do not display any meaningful affinity to IL-2Rb (Rickert et al., 2004) . As a result, sgc proteins effectively outcompete membrane gc protein for binding to proprietary cytokine receptors IL-2Rb and IL-7Ra. Therefore, upon dimerization, sgc proteins acquire binding specificities that make them distinct from monomeric sgc and membrane gc proteins. In this regard, we think it is not a coincidence that alternative splicing of sgc pre-mRNA creates a new C-terminal cysteine residue that promotes disulfide linkage and dimerization of sgc proteins. Indeed, we found such de novo C-terminal cysteine residues in both mouse and human sgc proteins, indicating that dimerization of sgc proteins is an evolutionary conserved mechanism of regulating cytokine signaling.
Soluble cytokine receptors have been observed in previous studies (Baran et al., 1988; Mortier et al., 2004; Nielsen et al., 1998) . Expression of soluble cytokine receptors had been associated with inflammation, autoimmunity, and cancer (Heaney and Golde, 1996) , but it was uncertain whether their expression was the cause or the consequence of immune activation. In theory, soluble cytokine receptors might either potentiate or antagonize cytokine signaling (Heaney and Golde, 1996) . Soluble IL-6Ra, for example, directly binds IL-6 and potently enhances IL-6 signaling (Rose-John, 2012), whereas soluble IL-15Ra sequesters IL-15 and prevents it from binding to membrane IL-15 receptors (Mortier et al., 2004) . gc proteins, however, do not show significant binding affinity to free cytokines, so it was not immediately obvious what role soluble gc would play in cytokine signaling. By using recombinant sgc proteins and sgc transgenic mice, we have demonstrated that sgc antagonizes IL-2 and IL-7 signaling and increases inflammatory immune responses.
Because T cell activation induces sgc production and sgc in turn induces inflammatory cytokine expression, sgc production is a mechanism to reinforce proinflammatory immune responses downstream of T cell activation. In fact, sgc expression would limit IL-2 responses and promote effector T cell differentiation. Thus, our present results provide an explanation for earlier reports on soluble gc expression in which a significant correlation was found in Crohn's disease patients between disease activity and serum gc levels (Nielsen et al., 1998) . According to our present findings, increased soluble gc expression would dampen gc cytokine signaling, which would enhance inflammatory cell activation to worsen the disease outcome. In agreement with our perspective, soluble gc is highly expressed under inflammatory conditions in both humans and mice. Soluble gc was abundantly expressed in synovial fluid of patients with rheumatoid arthritis and also highly induced in mice challenged with L. major (Meissner et al., 2001; Nishio et al., 2001 ). We also found that EAE disease outcome and in vivo inflammatory responses were exacerbated in sgcTg mice. Collectively, these data indicate a role for sgc as an active inducer of pathogenic T cells and inflammation.
Because sgc promotes inflammation, it is interesting to speculate whether neutralization of serum sgc expression would ameliorate inflammatory disease and dampen destructive T cell responses. The striking reduction in disease severity of EAE or IBD-induced mgcTg mice lacking sgc observed here suggests that depletion of sgc might be an effective therapy in patients suffering from inflammatory immune diseases. In this regard, the 9 aa C-terminal neoepitope CLQFPPSRI (and the 7 aa neoepitope RCPEFPP in humans) of sgc provides an excellent target for intervention with neutralizing antibodies. These peptide epitopes are generated only upon alternative splicing of gc pre-mRNA exon 5 to exon 7, and they are found only in sgc and not in membrane gc proteins. In contrast to conventional gc-specific antibodies, C-terminal sgc-specific antibodies will neutralize only alternatively spliced sgc proteins, making this epitope an attractive target to clear sgc from circulation without affecting membrane gc receptor function.
Discovery of the unique C-terminal sgc epitope was enlightening because it helped us identify the molecular origin of sgc. Specifically, the 9 aa C-terminal sequence is not found in membrane gc proteins so that its presence in serum directly demonstrated that sgc proteins are products of alternative RNA splicing. Error bars represent mean and SEM.
Soluble cytokine receptors are usually produced by one of the following two major mechanisms; proteolytic cleavage and shedding of membrane cytokine receptors or alternative splicing of cytokine receptor pre-mRNA (Levine, 2004) . TNF receptors are classical examples of cytokine receptors that are cleaved by transmembrane metalloproteinases and shed from cells (Hwang et al., 1993) . Soluble IL-6 receptors, on the other hand, are usually generated by alternative splicing (Horiuchi et al., 1994) . Our data document that sgc is exclusively produced by alternative splicing. It is conceivable that genetic variations might also contribute to increased sgc expression. In fact, IL-7Ra gene polymorphisms can result in increased expression of soluble IL-7Ra (sIL7Ra) (Gregory et al., 2007) , and sIL7Ra expression has been proposed as a significant risk factor for multiple sclerosis in humans (Harley, 2007; Lundströ m et al., 2013) . Specifically, these SNPs led to exclusion of exon 6 during IL-7Ra pre-mRNA splicing and resulted in the deletion of the transmembrane domain to produce soluble IL-7R proteins (Goodwin et al., 1990; Gregory et al., 2007) . It would be interesting to assess gc genes for genetic variations that increase exon 6 exclusion and to test whether such SNPs are associated with increased risk for MS or other autoimmune disease. Potentially, such gc genetic variations could predispose carriers to excessive inflammatory responses by increased levels of sgc.
In conclusion, the present study has identified sgc as an endogenous regulatory mechanism that dampens T cell signaling to gc cytokines and results in enhanced activity of Th17 cells. Enforced sgc expression constrained T cell survival under homeostatic conditions and promoted a proinflammatory environment under immune activation. Reciprocally, in vivo sgc deficiency suppressed inflammatory Th17 cell differentiation and effectively reduced the severity of Th17-cell-mediated autoimmune disease. Thus, sgc represents a naturally occurring immunomodulator of T cells and introduces a target for intervention in inflammation and disease.
EXPERIMENTAL PROCEDURES Animals C57BL/6 (B6) mice and B6.Ly5.2 mice were obtained from the Jackson Laboratory. Ctla4 The gc-and sgc-transgenic constructs were generated by ligating a murine gc or sgc cDNA into human CD2 (hCD2) enhancer-promoter-based vectors, respectively, and injected into fertilized B6 oocytes to generate gcTg and sgcTg mice. Animal experiments were approved by the National Cancer Institute Animal Care and Use Committee (ACUC), and all mice were cared for in accordance with US NIH guidelines.
Surface Plasmon Resonance
Purified mouse IL-2Rb ectodomain expressed from yeast was purchased from MyBiosource and used without further modification. IL-2Rb was aminecoupled to a CM5 sensor chip after buffer exchange into PBS (pH 7.4) via a NAP-5 (GE Healthcare) column by similar methods described previously (McElroy et al., 2012) . Concentration series of monomer and dimer forms of insect-cell-derived rsgc were injected over immobilized IL-2Rb at a flow rate of 25 ml/min via HBS-EP (pH 7.4). Surface plasmon resonance (SPR) experiments were performed at 25 C with a Biacore 3000 instrument (GE Healthcare). SPR sensorgrams were double-referenced and trimmed with BIAevaluation 4.1 (GE Healthcare). Dose-response curves (R max versus [rsgcmonomer or dimer]) were fit with Prism5.0 (GraphPad). Experiments were performed in triplicate.
Detection of Soluble Cytokine and Receptor Levels
Serum sgc was detected in a sandwich ELISA with gc-specific polyclonal antibodies (R&D Systems) as capture antibodies and biotin-conjugated gc-specific monoclonal antibodies (4G3; BD) as detection antibodies. Recombinant sgc protein was used as positive control. IL-2, IFN-g, TNF-a, and IL-17A were analyzed by ELISA according to the manufacturer's instructions (R&D Systems).
In Vitro CD4 + T Helper Cell Differentiation
Naive CD4 + T cells were electronically sorted by gating on CD62L + CD44 lo CD25 À cells. Sorted cells were stimulated with plate-bound a-CD3 and a-CD28 and cultured under nonskewing Th0 cell conditions (medium alone) or were differentiated into Th17 cells with human TGF-b1 (5 ng/ml; Peprotech), mouse IL-6 (30 ng/ml; BD), anti-mouse IL-4 (10 mg/ml), and anti-mouse IFN-g (10 mg/ml).
Where indicated, human IL-2 (100 U/ml; NCI) or anti-mouse IL-2 (10 mg/ml; Becton Dickinson) or mouse rsgc (4 mg/ml) was added to the cell culture.
Cell Proliferation Assay
Naive CD8 responder T cells were labeled with CFSE (carboxyfluorescein diacetate succinimidyl ester; Invitrogen) and incubated with human IL-2 (10 mg/ml; Peprotech) for 2 or 3 days. Mann-Whitney test. Curves of body weight change were fitted with nonlinear regression and group difference was examined by slope and intercept. p values of less than 0.05 were considered significant. *p < 0.05, **p < 0.01, ***p < 0.001, and NS (not significant) (Student's two-tailed t test).
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